Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Prognosis of Prostate Cancer With Other Primary Malignancies

´ëÇѺñ´¢±â°úÇÐȸÁö 2014³â 55±Ç 5È£ p.327 ~ 334
ÀÓÁÖÇö, À¯´Þ»ê, Á¤Àΰ©, È«ÁØÇõ, ¾ÈÇÑÁ¾, ±èû¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÓÁÖÇö ( Lim Ju-Hyun ) 
University of Ulsan College of Medicine Gangneung Asan Hospital Department of Urology

À¯´Þ»ê ( You Dal-San ) 
University of Ulsan College of Medicine Asan Medical Center Department of Urology
Á¤Àΰ© ( Jeong In-Gab ) 
University of Ulsan College of Medicine Asan Medical Center Department of Urology
È«ÁØÇõ ( Hong Jun-Hyuk ) 
University of Ulsan College of Medicine Asan Medical Center Department of Urology
¾ÈÇÑÁ¾ ( Ahn Han-Jong ) 
University of Ulsan College of Medicine Asan Medical Center Department of Urology
±èû¼ö ( Kim Choung-Soo ) 
University of Ulsan College of Medicine Asan Medical Center Department of Urology

Abstract


Purpose: The objective was to investigate the clinicopathological characteristics and the prognosis of prostate cancer patients affected by other primary malignancies.

Materials and Methods: From 1990 to 2008, we retrospectively reviewed the medical records of 1,317 patients who underwent radical prostatectomy (RP) for prostate cancer. We assessed the effect of other primary malignancies on clinicopathological features, biochemical recurrence (BCR)-free survival, cancer-specific survival (CSS), and overall survival (OS).

Results: Of 1,317 patients, at least one additional other primary malignancy was detected in 187 patients (14.2%). A comparison of patient groups according to the presence or absence of other primary malignancies showed no significant differences in preoperative serum prostate-specific antigen concentrations, pathological Gleason scores, or pathological staging. Prostate cancer patients with other primary malignancies were older than patients without other primary malignancies (p<0.001). No significant differences in 5-year BCR-free survival (80.2% compared with 77.7%; p=0.656) or CSS (98.9% compared with 98.5%; p=0.733) were found between these groups, respectively. Five-year OS was significantly lower in prostate cancer patients with than in those without other primary malignancies (89.3% compared with 95.4%; p<0.001). Multivariate analysis showed that other primary malignancies diagnosed after RP for prostate cancer were independent predictors of OS (hazard ratio, 4.10; p<0.001) but not of BCR-free survival or CSS. Conversely, other primary malignancies diagnosed before RP for prostate cancer did not independently predict BCR-free survival, OS, or CSS.

Conclusions: Prostate cancer prognosis after RP is not dependent on the presence or absence of other primary malignancies. However, other primary malignancies diagnosed after RP for prostate cancer negatively affect OS.

Å°¿öµå

Neoplasms; Prognosis; Prostate; Recurrence

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS